Vedolizumab-Associated Hypereosinophilia and Hepatoxicity. Issue 11 (16th November 2022)

• Record Type: Journal Article
• Authors: De Marco, Davide; Bessissow, Talat; Marcus, Victoria; Benmassaoud, Amine
• Is Part Of: ACG Case Reports Journal. Volume 9:Issue 11(2022)
• Page Start: e00905
• Publication Date: 2022-11-16
• DOI: 10.14309/crj.0000000000000905
• Languages: English
• ISSNs: 2326-3253

Abstract

ABSTRACT: Vedolizumab, which is approved for the treatment of ulcerative colitis, has been associated with drug-induced liver injury because of an unclear mechanism. We describe the case of a 29-year-old man who presented with abnormal liver enzymes and peripheral hypereosinophilia after vedolizumab initiation. A complete workup for causes of hepatitis and hypereosinophilia was negative, and liver biopsy showed signs compatible with drug-induced liver injury. After the withdrawal of vedolizumab, the patient's eosinophil count and liver enzymes normalized. As vedolizumab becomes more prominent, it is important to understand the potential side-effect profile of vedolizumab.